Secondary: investigator‐rated reduction in severity in TLSSc and mTLSSd · people with moderate to severe chronic hand eczema
The review found no eligible studies for this question.
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: investigator‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg leads to higher primary: participant‐rated good/excellent control of symptoms compared with placebo (high certainty).
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic hand eczema
Oral retinoids: alitretinoin 10 mg showed no clear difference in primary: all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity of TLSSd · people with moderate to severe chronic hand eczema
1 finding from 1 review
Primary outcome: Global improvement of disease activity or damage assessed by a medical practitioner or by participants · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone may leads to higher primary outcome: Global improvement of disease activity or damage… compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Secondary outcome: Improvement of disease activity (reduction in lesion size) · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
Secondary outcome: Improvement of disease damage ‐ not measured · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · pityriasis rosea
Erythromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with resolution of itch within 2… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Azithromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo or vitamins (low certainty).
1 finding from 1 review
Minor participant‐reported adverse events not requiring withdrawal of the treatment: Mild abdominal pain. · pityriasis rosea
Azithromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo or vitamins (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review